PL4387730T3 - ROCK INHIBITOR CONSTANTS - Google Patents

ROCK INHIBITOR CONSTANTS

Info

Publication number
PL4387730T3
PL4387730T3 PL23776436.0T PL23776436T PL4387730T3 PL 4387730 T3 PL4387730 T3 PL 4387730T3 PL 23776436 T PL23776436 T PL 23776436T PL 4387730 T3 PL4387730 T3 PL 4387730T3
Authority
PL
Poland
Prior art keywords
rock inhibitor
inhibitor constants
constants
rock
inhibitor
Prior art date
Application number
PL23776436.0T
Other languages
Polish (pl)
Inventor
Andrew BELFIELD
Clifford D Jones
Richard Armer
Original Assignee
Redx Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2213103.1A external-priority patent/GB202213103D0/en
Priority claimed from GBGB2214708.6A external-priority patent/GB202214708D0/en
Application filed by Redx Pharma Limited filed Critical Redx Pharma Limited
Publication of PL4387730T3 publication Critical patent/PL4387730T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL23776436.0T 2022-09-08 2023-09-08 ROCK INHIBITOR CONSTANTS PL4387730T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2213103.1A GB202213103D0 (en) 2022-09-08 2022-09-08 Crystalline form of a rock inhibitor
GBGB2214708.6A GB202214708D0 (en) 2022-10-06 2022-10-06 Crystalline form of a rock inhibitor
PCT/GB2023/052341 WO2024052704A1 (en) 2022-09-08 2023-09-08 Solid forms of a rock inhibitor

Publications (1)

Publication Number Publication Date
PL4387730T3 true PL4387730T3 (en) 2025-09-22

Family

ID=88188945

Family Applications (1)

Application Number Title Priority Date Filing Date
PL23776436.0T PL4387730T3 (en) 2022-09-08 2023-09-08 ROCK INHIBITOR CONSTANTS

Country Status (20)

Country Link
US (1) US20260078108A1 (en)
EP (2) EP4387730B1 (en)
JP (2) JP2024534810A (en)
KR (1) KR20250057882A (en)
CN (1) CN119894884A (en)
AU (1) AU2023336823A1 (en)
CA (1) CA3262882A1 (en)
DK (1) DK4387730T3 (en)
ES (1) ES3040251T3 (en)
FI (1) FI4387730T3 (en)
HR (1) HRP20251018T1 (en)
HU (1) HUE073310T2 (en)
IL (1) IL319110A (en)
LT (1) LT4387730T (en)
MX (1) MX2025002776A (en)
PL (1) PL4387730T3 (en)
PT (1) PT4387730T (en)
SI (1) SI4387730T1 (en)
SM (1) SMT202500313T1 (en)
WO (1) WO2024052704A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202403179D0 (en) 2024-03-05 2024-04-17 Redx Pharma Plc Method of making kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60115077T2 (en) * 2000-09-29 2006-06-29 Bristol-Myers Squibb Co. DYNAMIC SEPARATION OF ISOMERS AND ISOLATED ISOMERS
PE20081889A1 (en) * 2007-03-23 2009-03-05 Smithkline Beecham Corp INDOL CARBOXAMIDES AS INHIBITORS OF IKK2
JP2014525425A (en) * 2011-08-31 2014-09-29 アマケン エンヴェー Novel ROCK kinase inhibitor
SMT201700317T1 (en) * 2013-01-29 2017-09-07 Redx Pharma Plc Pyridine derivatives as soft rock inhibitors
US9562121B2 (en) * 2013-02-12 2017-02-07 National University Corporation Kanazawa University Optically active poly(diphenylacetylene) compound, preparation method therefor, and use thereof as optical isomer separating agent
KR102720461B1 (en) * 2016-01-22 2024-10-21 잔센파마슈티카엔.브이. Novel 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
AU2018241940B2 (en) * 2017-04-01 2023-09-28 Adeptio Pharmaceuticals Limited Dihydrotetrabenazine for use in the treatment a movement disorder
JP7576581B2 (en) * 2019-06-27 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド Imidazo[1,2-a]pyridinyl derivatives and their use in the treatment of diseases - Patents.com

Also Published As

Publication number Publication date
IL319110A (en) 2025-04-01
US20260078108A1 (en) 2026-03-19
DK4387730T3 (en) 2025-09-01
JP2025090729A (en) 2025-06-17
PT4387730T (en) 2025-08-27
KR20250057882A (en) 2025-04-29
CA3262882A1 (en) 2024-03-14
LT4387730T (en) 2025-09-10
JP2024534810A (en) 2024-09-26
ES3040251T3 (en) 2025-10-29
WO2024052704A1 (en) 2024-03-14
CN119894884A (en) 2025-04-25
EP4520746A3 (en) 2025-06-04
EP4387730A1 (en) 2024-06-26
MX2025002776A (en) 2025-04-02
EP4387730B1 (en) 2025-05-28
HUE073310T2 (en) 2026-01-28
HRP20251018T1 (en) 2025-10-24
SMT202500313T1 (en) 2025-09-12
EP4520746A2 (en) 2025-03-12
AU2023336823A1 (en) 2025-02-20
FI4387730T3 (en) 2025-08-25
SI4387730T1 (en) 2025-10-30

Similar Documents

Publication Publication Date Title
EP4495113A4 (en) KIF18A Inhibitor
EP4110333A4 (en) SOS1 INHIBITORS
EP4216951A4 (en) KRAS-G12D INHIBITORS
EP4434979A4 (en) KIF18A Inhibitor
DK4337652T3 (en) NLRP3 inhibitors
EP4332103A4 (en) SULFOXIMINE-CONTAINING ATR INHIBITOR COMPOUND
EP4197538A4 (en) EGFR INHIBITORS
IL314887A (en) Parg inhibitors
IL315027A (en) NLRP3 inhibitors
PL4363406T3 (en) NLRP3 INFLAMASOME INHIBITORS
EP4358963A4 (en) SOS1 INHIBITORS
EP4168398A4 (en) TYK-2 INHIBITOR
EP4511367A4 (en) FAP inhibitor
IL321260A (en) POLQ inhibitors
EP3901156A4 (en) NITROOXY DERIVATIVE OF ROCK KINASE INHIBITOR
EP4247372A4 (en) PLASMAKALLIK INHIBITORS
EP4263502C0 (en) SARS-COV-2 MPRO INHIBITOR COMPOUNDS
EP4226919A4 (en) FERROPTOSE INHIBITORS
EP4210694A4 (en) PLASMAKALLIK INHIBITORS
EP4619388A4 (en) Cathepsin-L inhibitor
PL4387730T3 (en) ROCK INHIBITOR CONSTANTS
EP4257795C0 (en) Rock anchor
DK4323338T3 (en) TEAD inhibitors
EP4619617A4 (en) BOREHOLE OPTIMIZER
EP4448515A4 (en) PLPRO INHIBITORS